Cytokinetics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
January 06 2021 - 4:00PM
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that
Robert I. Blum, President and Chief Executive Officer, is scheduled
to participate in a virtual fireside chat at the H.C. Wainwright
BioConnect 2021 Virtual Conference taking place January 11-14,
2021.
The presentation will be available for on-demand
listening beginning January 11, 2021 at 6:00 AM Eastern Time.
Interested parties may access the recorded webcast of this
presentation by visiting the Investors & Media section of the
Cytokinetics website at www.cytokinetics.com. The webcast will be
archived on the Presentations page within the Investors & Media
section of Cytokinetics' website for 90 days following the
conclusion of the event.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical
company focused on discovering, developing and commercializing
first-in-class muscle activators and next-in-class muscle
inhibitors as potential treatments for debilitating diseases in
which muscle performance is compromised and/or declining. As a
leader in muscle biology and the mechanics of muscle performance,
the company is developing small molecule drug candidates
specifically engineered to impact muscle function and
contractility. Cytokinetics is preparing for regulatory
interactions for omecamtiv mecarbil, its novel cardiac muscle
activator, following positive results from GALACTIC-HF, a large,
international Phase 3 clinical trial in patients with heart
failure. Cytokinetics is conducting METEORIC-HF, a second Phase 3
clinical trial of omecamtiv mecarbil. Cytokinetics is also
developing CK-274, a next-generation cardiac myosin inhibitor, for
the potential treatment of hypertrophic cardiomyopathies (HCM).
Cytokinetics is conducting REDWOOD-HCM, a Phase 2 clinical trial of
CK-274 in patients with obstructive HCM. Cytokinetics is also
developing reldesemtiv, a fast skeletal muscle troponin activator
for the potential treatment of ALS and other neuromuscular
indications following conduct of FORTITUDE-ALS and other Phase 2
clinical trials. The company is considering potential advancement
of reldesemtiv to a Phase 3 clinical trial. Cytokinetics continues
its over 20-year history of pioneering innovation in muscle biology
and related pharmacology focused to diseases of muscle dysfunction
and conditions of muscle weakness.
For additional information about Cytokinetics,
visit www.cytokinetics.com and follow us on Twitter, LinkedIn,
Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any
intent or obligation to update these forward-looking statements and
claims the protection of the Act's Safe Harbor for
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating
to Cytokinetics' and its partners' research and
development activities of Cytokinetics’ product candidates. Such
statements are based on management's current expectations, but
actual results may differ materially due to various risks and
uncertainties, including, but not limited to the risks related
to Cytokinetics' business outlined
in Cytokinetics' filings with the Securities and
Exchange Commission. Forward-looking statements are not guarantees
of future performance, and Cytokinetics' actual results
of operations, financial condition and liquidity, and the
development of the industry in which it operates, may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements
that Cytokinetics makes in this press release speak only
as of the date of this press
release. Cytokinetics assumes no obligation to update its
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Contact:Cytokinetics
Diane Weiser
Senior Vice President, Corporate
Communications, Investor Relations(415) 290-7757
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Oct 2023 to Oct 2024